• Insight Guru analysis flagged a valuation reversal between Merck and Eli Lilly, with Merck now trading at a premium despite slower growth.
• Market pricing implies 52.2x price-to-operating-income for Merck versus 25.3x for Lilly, a flip from 10.3x versus 30x a year ago.
• Merck’s trailing operating income fell 64.8% over the last 12 months, inflating the multiple as investors focus on pipeline execution.
• Management points to more than $70 billion in commercial opportunity from over 20 new products to offset eventual Keytruda patent expiry.
• Lilly shows stronger momentum, with last-12-month revenue growth of 49.6% versus 4.6% for Merck, pressuring the premium’s justification.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Guru Inc. published the original content used to generate this news brief on September 10, 2026, and is solely responsible for the information contained therein.